Comparative Pharmacology
Head-to-head clinical analysis: RIBOCICLIB versus VERZENIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RIBOCICLIB versus VERZENIO.
RIBOCICLIB vs VERZENIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. Selectively inhibits CDK4 and CDK6, leading to reduced phosphorylation of retinoblastoma protein, G1-to-S phase cell cycle arrest, and decreased proliferation of estrogen receptor-positive breast cancer cells.
Selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which prevents phosphorylation of retinoblastoma protein, blocking cell cycle progression from G1 to S phase and reducing cancer cell proliferation.
600 mg orally once daily for 21 consecutive days followed by 7 days off treatment, in combination with an aromatase inhibitor or fulvestrant.
150 mg orally twice daily.
None Documented
None Documented
Clinical Note
moderateRibociclib + Gatifloxacin
"The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Gatifloxacin."
Clinical Note
moderateRibociclib + Levofloxacin
"The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Levofloxacin."
Clinical Note
moderateRibociclib + Sparfloxacin
"The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Sparfloxacin."
Clinical Note
moderateRibociclib + Haloperidol
Terminal elimination half-life is 32.0 hours (range 29.2–40.4 hours), supporting once-daily dosing.
Terminal elimination half-life is approximately 18 hours; supports once-daily dosing. Clinically, steady-state is achieved within 5 days.
Primarily hepatic metabolism (CYP3A4) with fecal excretion as major route (69% of dose as metabolites, 23% unchanged in feces); renal excretion accounts for approximately 12% (primarily as metabolites, <1% unchanged).
Primarily fecal (≥91%) as unchanged parent drug and metabolites; renal excretion accounts for <1%.
Category C
Category C
CDK4/6 Inhibitor
Cyclin-Dependent Kinase 4/6 Inhibitor
"The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Haloperidol."